ZYME:NASDAQ
Zymeworks Inc
26,57 $
arrow_downward
-3,31%(-0,91) 1 d.
26,57 $
0,00% (0,00)
bedtimePēctirdzniecības
Slēgts: 18. sept., 16:00:01 GMT-4 · USD
search
Visi simboli
1 d.
5 d.
1 m.
6 m.
Š.g.
1 g.
5 g.
Maks.
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: ZYME…
Atvērt
27,45 $
Augsta
27,55 $
Zema
26,38 $
Tirgus kapitalizācija
1,89 mljrd.
Vid. apjoms
722,08 tūkst.
Apjoms
1,10 milj.
Augstākā 52 ned.
31,34 $
Zemākā 52 ned.
15,82 $
Peļņa uz vienu akciju
-2,01 $
Beta
1,19
Apgrozībā esošās akcijas
70,96 milj.
Darbinieku skaits
231
Atvērt
27,45 $
Augsta
27,55 $
Zema
26,38 $
Tirgus kapitalizācija
1,89 mljrd.
Vid. apjoms
722,08 tūkst.
Apjoms
1,10 milj.
Augstākā 52 ned.
31,34 $
Zemākā 52 ned.
15,82 $
Peļņa uz vienu akciju
-2,01 $
Beta
1,19
Apgrozībā esošās akcijas
70,96 milj.
Darbinieku skaits
231
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
TipRanks
·
pirms 2 stundām
Theravance Shareholders Approve Merger with Zymeworks Inc.
Investing.com Canada
·
pirms 3 stundām
Theravance Biopharma shareholders approve merger with Zymeworks By Investing.com
Seeking Alpha
·
pirms 5 stundām
Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow (NASDAQ:ZYME)
AD HOC NEWS
·
pirms 11 stundām
Zymeworks stock gains as Theravance deal and valuation draw investor focus
Profils
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
Par “Zymeworks Inc”
ĢenerāldirektorsKenneth Galbraith
Darbinieki231
Dibināšanas datums2003
Galvenais birojsMiddletown, Delavēra, Amerikas Savienotās Valstis
Sektors-
Tīmekļa vietnezymeworks.com